Soligenix Inc., a late-stage biopharmaceutical company developing treatments for rare diseases, has been featured in a NetworkNewsAudio APR highlighting the growing impact of chronic and rare conditions on older Americans. The feature, titled "Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now," emphasizes that more than 30 million Americans are affected by such conditions, with most lacking FDA-approved therapies.
The company's lead candidate, HyBryte(TM) for cutaneous T-cell lymphoma (CTCL), is now in the final confirmatory trial needed before global marketing submissions. This progress positions Soligenix at a crucial juncture as the administration advances new health policy initiatives related to chronic and rare diseases. The company's Specialized BioTherapeutics business segment is developing HyBryte as a novel photodynamic therapy utilizing safe visible light for CTCL treatment.
Following successful completion of the second Phase 3 study, Soligenix will seek regulatory approvals to support potential commercialization worldwide. The development pipeline also includes expansion of synthetic hypericin into psoriasis, first-in-class innate defense regulator technology dusquetide for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behçet's Disease. Additional information about the company's progress is available in their newsroom at https://ibn.fm/SNGX.
The Public Health Solutions business segment includes development programs for RiVax(R) ricin toxin vaccine candidate, vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax(TM) for COVID-19 prevention. These programs incorporate the proprietary heat stabilization platform technology ThermoVax(R) and have been supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The timing of Soligenix's advancement coincides with increasing recognition of rare disease burdens in healthcare policy discussions. With most rare disease patients lacking approved treatment options, successful development of therapies like HyBryte could address significant unmet medical needs while potentially establishing new treatment paradigms for chronic conditions affecting aging populations. The company's progress represents both a scientific advancement and a response to evolving public health priorities.
